Pardes Bioscience Inc. (NASDAQ: PRDS) has announced a late-breaker poster presentation sharing clinical findings from the current PBI-0451 Phase 1 study to be presented at the 29th Conference On Retroviruses And Opportunistic Infections 2022 that will take place Virtually between February 12 and 16, 2022.
Pardes to present PBI-045 findings at CROI
The poster presentation titled, “PBI-0451 an orally administered 3CL protease inhibitor of SARS-CoV-2 for COVID-19” will be presented during the New Antivirals for SARS-CoV-2: Activity in vitro and in vivo session on Tuesday, February 15, 2022. Following the presentation, the full poster will be available on the company’s website.
PBI-0451 is an experimental orally accessible direct-acting antiviral (DAA) blocker of Mpro, an important protein for coronavirus reproduction, including the new SARS-CoV-2 that cause COVID-19. All coronaviruses, including current and emergent coronavirus variations, have a protease that is very similar. The drug PBI-0451 is under development to treat and prevent SARS-CoV-2 infections and related illnesses. PBI-0451 is already being tested in healthy subjects in New Zealand in a first Phase randomized, blinded, placebo-controlled dose-escalation research to determine its tolerability, safety and pharmacokinetics following single and multiple ascending dosages.
Phase 1 results support the continued development of PBI-0451.
The company’s CEO, Uri Lopatin, said, “We are highly encouraged by these initial Phase 1 observations, which support the continued development of PBI-0451 as a potential stand-alone antiviral therapy for the treatment and prevention of SARS-CoV-2 infections. COVID-19 continues to take the lives of over 2,000 people a day in the United States alone and disrupts healthcare globally. Additional treatment options with the potential to treat current and emerging variants, such as protease inhibitors, continue to be needed. We are excited to continue advancing our lead protease inhibitor PBI-0451 and bring our novel oral antiviral treatment one step closer to patients in need.”
PBI-0451’s pharmacokinetics were not significantly changed when co-administered with ritonavir, a powerful P-glycoprotein/CYP450 3A antagonist, in a drug interaction group.
